Mackinnon, Erin S. http://orcid.org/0000-0001-9736-6970
Leiter, Lawrence A. http://orcid.org/0000-0002-1040-6229
Wani, Rajvi J. http://orcid.org/0000-0002-2422-7758
Burke, Natasha http://orcid.org/0000-0001-7319-4369
Shaw, Eileen http://orcid.org/0000-0001-6537-1898
Witges, Kelcie http://orcid.org/0000-0002-0960-0761
Goodman, Shaun G. http://orcid.org/0000-0001-8068-2440
Funding for this research was provided by:
Amgen Canada
Article History
Received: 20 November 2023
Accepted: 9 January 2024
First Online: 29 January 2024
Declarations
:
: This study was sponsored by Amgen Canada Inc. (Amgen). Erin S. Mackinnon, Rajvi J. Wani, and Natasha Burke are employed by Amgen, who funded this study and hold Amgen stock. Lawrence A. Leiter has received research support from, has provided CME on behalf of and/or has acted as an advisor to Amarin, Amgen, AstraZeneca, Esperion, HLS, Kowa, Merck, Novartis, Pfizer, and Sanofi. Eileen Shaw and Kelcie Witges are employed by Medlior Health Outcomes Research Ltd., which received funding for the study from Amgen. Shaun G. Goodman reports research grant support (e.g., steering committee or data and safety monitoring committee) and/or speaker/consulting honoraria (e.g., advisory boards) from: Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, CYTE Ltd., Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma; and salary support/honoraria from the Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, TIMI Study Group (Brigham Health).
: The study complies with the Declaration of Helsinki and was approved by the Health Research Ethics Board of Alberta–Community Health Committee (HREBA-CHC). Patient consent for participation was waived.